Davion Healthcare (DAVI) Registration filing summary

Company overview and business model

• Develops four completed non-invasive, non-diagnostic home tests: BreastCheck, FootFlow, Testic and ThermaDerm; results flag potential anomalies requiring clinical follow-up.

• Thermography uses liquid-crystal film to map skin-temperature differences; AI analysis of smartphone images is intended to standardize results.

• Licensing is the core model: commercial partners handle manufacturing, marketing, sales and distribution; license fees and royalties are expected to drive revenue.

• BreastCheck is expected to launch in the U.S. in H1 2026 under NeuRX's global license; FootFlow is anticipated six months later, with Europe and U.K. launches subject to market conditions.

Financial performance and metrics

• Pre-revenue through the filing; operating loss was €0.3M for H1 2025 vs. €1.1M for H1 2024, and €1.3M for FY2024 vs. €5.3M for FY2023.

• Cash was €4,396 at June 30, 2025; related-party advances were €321,084. CEO-linked funding has supported operating needs.

• Executive and director remuneration was waived until Nasdaq listing, lowering 2025 reported costs; public-company compliance and restored compensation are expected to raise expenses after listing.

• NeuRX's license includes $120M in staged fees and minimum royalties of $10M per Contract Year; management cited CEO support and anticipated license inflows for at least 12 months of liquidity.

Use of proceeds and capital allocation

• No primary shares are being offered; resale proceeds, if any, go to registered shareholders, not to the issuer.

• Estimated listing costs of $921,900 are to be funded through non-interest-bearing, unsecured advances from Malbrite Ltd., owned by CEO Jack Kaye, repayable only after a future capital raise.

• Available funds and future earnings are intended to support operations and expansion; no cash dividends are planned for the foreseeable future.